Clinical trial · Observational
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
Analysis of the Occurrence Time of Bone Metastasis and Disease Treatment Patterns in Patients with Breast Cancer Bone Metastasis: a Retrospective Study from China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
By analyzing the clinical data of patients with advanced breast cancer with bone metastasis admitted to our center from January 1, 2021 to February 28, 2023, this study aims to understand the real-world clinical diagnosis and treatment of breast cancer with bone metastasis, including the epidemiology of bone metastasis, screening and diagnosis methods, selection of clinical treatment methods, and occurrence of SRE. To explore the risk factors related to bone metastasis-free survival (BMFI). In addition, we will explore the use of quantitative analysis of CT values to evaluate bone metastases of breast cancer, aiming to provide a new method for imaging quantitative efficacy evaluation of bone metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Bone metastasis-free interval (BMFI) of breast cancer patients with bone metastasis
- timeFrame
- From the diagnosis of breast cancer to the occurrence of bone metastasis，assessed up to 100 months
- description
- Bone metastasis-free interval (BMFI) is the time between diagnosis of breast cancer and the onset of bone metastases
Secondary outcomes (4)
- measure
- Number of participants with Clinical features of bone metastasis
- timeFrame
- From the diagnosis of breast cancer to the conclusion of the study period，assessed up to 100 months
- description
- Clinical characteristics of patients with bone metastasis include age, menstrual status, body mass index (BMI), presence or non-presence of underlying disease, tumor location, primary tumor size, number of lymph node metastases, TNM stage, pathologic type, histological classification, vascular thrombus invasion, estrogen receptor (ER) status, progesterone receptor (PR) status, and other factors. Human epidermal growth factor receptor-2 (HER-2) expression, Ki-67 level, whether chemotherapy and radiotherapy, recurrence and metastasis time, recurrence and metastasis site.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18y; 2. Advanced breast cancer is clearly diagnosed; 3. Imaging or pathology confirmed at least 1 bone metastasis; 4. No history of other malignant tumors at the time of initial diagnosis; 5. The physical status score of Eastern Tumor Collaboration Group (ECOG) was ≤2 points; 6. Complete clinical and follow-up data. Exclusion Criteria: Exclusion is defined as meeting 1 of the following exclusion criteria: 1. Patients with other malignant tumors; 2. History of hyperthyroidism and hypothyroidism, abnormal parathyroid function; 3. History of bone metabolic diseases.
References
Publications (0)
Data not yet available